Recon: FDA rejects Shin Nippon’s nasal migraine drug over manufacturing issues; GAO to review FDA’s oversight of device recalls
ReconJason Scott
Biologics/ biosimilars/ vaccinesEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyUnited States